Tag Archives: R&D
By William Looney | Published: January 11, 2012
Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues, because if you cannot justify your costs how do you expect to prevail on price?
By Jennifer Ringler | Published: December 5, 2011
The hard (declining) numbers of approved NMEs in the past 10 to 15 years tell a powerful story. But is it the whole story?
By William Looney | Published: October 19, 2011
High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty. If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what count [...]
By Guest Blogger | Published: July 14, 2011
Leniency and staff reward/recognition are key to improving R&D and product innovation, according to the first of three new Economist Intelligence Unit reports. Innovation Imperative in Biopharma focuses on the how to curb wasteful R&D spending and how to strengthen innovation abilities. The study is based on a survey of 282 senior executives, each of [...]
By William Looney | Published: June 29, 2011
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk. The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]